Articles producció científica> Medicina i Cirurgia

Fondaparinux in the initial and long-term treatment of venous thromboembolism

  • Dades identificatives

    Identificador: imarina:4681102
    Autors:
    Pesavento R, Amitrano M, Trujillo-Santos J, Di Micco P, Mangiacapra S, López-Jiménez L, Falgá C, García-Bragado F, Piovella C, Prandoni P, Monreal M, RIETE Investigators.
    Resum:
    Background: Even in the absence of evidence on its long-term efficacy and safety, a number of patients with venous thromboembolism (VTE) receive long-term therapy with fondaparinux alone in everyday practice. Methods: We used the Registro Informatizado de Enfermedad Tromboembólica (RIETE) registry to compare the rate of VTE recurrences and major bleeding at 10 and 90 days in patients with and without cancer. For long-term therapy, fondaparinux was compared with vitamin K antagonists (VKA) in patients without cancer and with low-molecular- weight heparin (LMWH) in those with cancer Results Of 47,378 patients recruited, 46,513 were initially treated with heparin, 865 with fondaparinux. Then, 263 patients (78 with cancer) were treated for at least 3 months with fondaparinux. After propensity-score matching, there were no differences between patients receiving initial therapy with heparin or fondaparinux. Among patients with cancer, there were no differences between fondaparinux and LMWH. Among patients without cancer, the long-term use of fondaparinux was associated with an increased risk of major bleeding (3.24 % vs. 0.95 %, p < 0.05). Conclusions: An unexpected high rate of major bleeding was observed in non-cancer patients treated with longterm fondaparinux. Our small sample does not allowto derive relevant conclusions on the use of fondaparinux in cancer patients.
  • Altres:

    Autor segons l'article: Pesavento R, Amitrano M, Trujillo-Santos J, Di Micco P, Mangiacapra S, López-Jiménez L, Falgá C, García-Bragado F, Piovella C, Prandoni P, Monreal M, RIETE Investigators.
    Departament: Medicina i Cirurgia
    Autor/s de la URV: Porras Ledantes, Jose Antonio
    Paraules clau: Venous thromboembolism Pulmonary embolism Fondaparinux Drug therapy Deep vein thrombosis Anticoagulants pulmonary embolism fondaparinux drug therapy deep vein thrombosis anticoagulants
    Resum: Background: Even in the absence of evidence on its long-term efficacy and safety, a number of patients with venous thromboembolism (VTE) receive long-term therapy with fondaparinux alone in everyday practice. Methods: We used the Registro Informatizado de Enfermedad Tromboembólica (RIETE) registry to compare the rate of VTE recurrences and major bleeding at 10 and 90 days in patients with and without cancer. For long-term therapy, fondaparinux was compared with vitamin K antagonists (VKA) in patients without cancer and with low-molecular- weight heparin (LMWH) in those with cancer Results Of 47,378 patients recruited, 46,513 were initially treated with heparin, 865 with fondaparinux. Then, 263 patients (78 with cancer) were treated for at least 3 months with fondaparinux. After propensity-score matching, there were no differences between patients receiving initial therapy with heparin or fondaparinux. Among patients with cancer, there were no differences between fondaparinux and LMWH. Among patients without cancer, the long-term use of fondaparinux was associated with an increased risk of major bleeding (3.24 % vs. 0.95 %, p < 0.05). Conclusions: An unexpected high rate of major bleeding was observed in non-cancer patients treated with longterm fondaparinux. Our small sample does not allowto derive relevant conclusions on the use of fondaparinux in cancer patients.
    Àrees temàtiques: Saúde coletiva Química Psicología Peripheral vascular disease Medicina iii Medicina ii Medicina i Interdisciplinar Hematology General medicine Farmacia Ensino Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología Biodiversidade Astronomia / física
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    Adreça de correu electrònic de l'autor: joseantonio.porras@urv.cat
    Identificador de l'autor: 0000-0001-6418-1822
    Data d'alta del registre: 2024-09-07
    Versió de l'article dipositat: info:eu-repo/semantics/submittedVersion
    Enllaç font original: https://www.thrombosisresearch.com/article/S0049-3848(14)00666-5/fulltext#secst0060
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referència a l'article segons font original: Thrombosis Research. 135 (2): 311-317
    Referència de l'ítem segons les normes APA: Pesavento R, Amitrano M, Trujillo-Santos J, Di Micco P, Mangiacapra S, López-Jiménez L, Falgá C, García-Bragado F, Piovella C, Prandoni P, Monreal M, (2015). Fondaparinux in the initial and long-term treatment of venous thromboembolism. Thrombosis Research, 135(2), 311-317. DOI: 10.1016/j.thromres.2014.11.032
    DOI de l'article: 10.1016/j.thromres.2014.11.032
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2015
    Tipus de publicació: Journal Publications
  • Paraules clau:

    Hematology,Peripheral Vascular Disease
    Venous thromboembolism
    Pulmonary embolism
    Fondaparinux
    Drug therapy
    Deep vein thrombosis
    Anticoagulants
    pulmonary embolism
    fondaparinux
    drug therapy
    deep vein thrombosis
    anticoagulants
    Saúde coletiva
    Química
    Psicología
    Peripheral vascular disease
    Medicina iii
    Medicina ii
    Medicina i
    Interdisciplinar
    Hematology
    General medicine
    Farmacia
    Ensino
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Biotecnología
    Biodiversidade
    Astronomia / física
  • Documents:

  • Cerca a google

    Search to google scholar